Delivery Order SPE2DB20D3303-SPE2DB25FA2LN
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency on September 12, 2025, for the supply of Betaseron 0.3 mg kits valued at $16,778.88. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 15, 2025, and will be performed at the company's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of the company's pharmaceutical supply relationship with DLA, which procures medical supplies...
- The Defense Logistics Agency awarded a delivery order valued at $43,600.80 to AmerisourceBergen Drug Corp for Betaseron 0.3 mg kits, with a completion date of July 22, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems....
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for Betaseron 0.3 mg kits with a ceiling value of $82,716.10 under a firm fixed-price contract type. The award, issued on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $22,385.72 to AmerisourceBergen Drug Corp for the supply of Betaseron 0.3 mg kits under a firm fixed price contract. This competitively awarded, non-set-aside delivery order was executed on September 9, 2025, with an ultimate completion date of September 10, 2025. The products will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and pharmaceutical...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $16,226.87 firm-fixed-price delivery order is for the medication Betaseron 0.3 mg kits. The contract has an ultimate completion date of May 1, 2025. Amerisourcebergen Drug Corp is a for-profit organization that serves as a critical supplier of medical and pharmaceutical products to federal agencies, particularly the DLA. The company holds a substantial...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 7, 2025, for $61,750.04 to supply Betaseron 0.3 mg kits. This is a firm fixed-price delivery order with an ultimate completion date of July 8, 2025, and performance will be executed at the contractor's Conshohocken, Pennsylvania facility. The award was made without a set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, a major...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has received a firm fixed price delivery order contract from the Defense Logistics Agency (DLA) Troop Support Medical valued at $14,734.37. The contract is for the delivery of 0.3 mg BETASERON medication kits, which are specialty pharmaceutical products used to treat certain medical conditions. This delivery order contract does not have a set-aside designation and is part of a larger indefinite delivery contract (IDC)...
- This federal contract award, valued at $16,526.82, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is for the delivery of Betaseron 0.3 mg kits, a specialty medication, with a completion date of December 22, 2022. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the supply of Betaseron 0.3 mg kits, a pharmaceutical product, to the Defense Logistics Agency (DLA). The firm-fixed-price delivery order has a ceiling value of $51,064.44 and an ultimate completion date of June 21, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with the DLA Troop Support Medical through December 31, 2025. This single-award IDC...
- This federal contract award is for the delivery of BETASERON 0.3 MG KITS to the Defense Logistics Agency, a defense agency. The contract has a ceiling value of $39,584.02 and is a Firm Fixed Price Delivery Order with Amerisourcebergen Drug Corp as the prime contractor. The contract is not set-aside and has an ultimate completion date of May 29, 2025. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that has a significant Indefinite Delivery...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2LNDelivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $6,266.27 by the Defense Logistics Agency on August 12, 2025, for the supply of Betaseron 0.3 mg kits. This firm fixed-price delivery order, which carries an ultimate completion date of August 13, 2025, represents a competitively awarded contract with no set-aside designation. The award is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company's extensive portfolio of federal contract awards demonstrates its capability to fulfill diverse pharmaceutical requirements, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. This delivery order for Betaseron, an interferon beta-1b treatment commonly used for multiple sclerosis management, exemplifies the company's role as a prime vendor in supporting Defense Health Agency healthcare requirements through the DLA's global pharmaceutical procurement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.3k | 8/12/25 |